2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value
2019
Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience
Krakora R, Shih W, Popli P, Gorshein E, Salaru G, David K, Bannerji R. Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience. Blood 2019, 134: 5071. DOI: 10.1182/blood-2019-129390.Peer-Reviewed Original ResearchProgression-free survivalAllogeneic stem cell transplantAcute lymphoblastic leukemiaTime of diagnosisAchievement of CRBetter overall survivalOverall survivalComplete remissionInsurance statusAcute myeloblastic leukemiaSurvival outcomesLymphoblastic leukemiaRegeneron PharmaceuticalsHealth insuranceSurvival rateSingle comprehensive cancer centerBetter progression-free survivalWorse progression-free survivalProportional hazards regression methodsPhiladelphia chromosome statusSingle-center experienceRetrospective chart reviewStem cell transplantComprehensive cancer centerLack of insurance